TRKC (G623R/L686M)
Sign in to save this workspaceNTRK3 · Variant type: compound · HGVS: p.G623R;p.L686M
Components
p.G623Rp.L686M
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Darovasertib | 84.0% | 16.0% | 96.99 |
| 2 | Repotrectinib | 82.5% | 17.5% | 84.21 |
| 3 | Ponatinib | 79.5% | 20.5% | 78.23 |
| 4 | Cabozantinib | 42.6% | 57.4% | 92.73 |
| 5 | Pacritinib | 40.3% | 59.7% | 88.64 |
| 6 | Tivozanib | 31.7% | 68.3% | 92.42 |
| 7 | Ripretinib | 22.0% | 78.0% | 92.95 |
| 8 | Brigatinib | 15.4% | 84.6% | 82.96 |
| 9 | Defactinib | 14.7% | 85.3% | 92.68 |
| 10 | Quizartinib | 13.5% | 86.5% | 99.50 |
| 11 | Crizotinib | 12.2% | 87.8% | 91.39 |
| 12 | Pralsetinib | 11.6% | 88.4% | 93.43 |
| 13 | Abrocitinib | 11.2% | 88.8% | 99.50 |
| 14 | Sorafenib | 9.6% | 90.4% | 96.72 |
| 15 | Bosutinib | 8.0% | 92.0% | 87.22 |
| 16 | Idelalisib | 6.1% | 93.9% | 100.00 |
| 17 | Asciminib | 5.7% | 94.3% | 100.00 |
| 18 | Regorafenib | 5.1% | 94.9% | 95.99 |
| 19 | Avapritinib | 4.9% | 95.1% | 97.73 |
| 20 | Selumetinib | 4.9% | 95.1% | 100.00 |
| 21 | Rabusertib | 4.8% | 95.2% | 98.74 |
| 22 | Futibatinib | 4.4% | 95.6% | 98.48 |
| 23 | Zanubrutinib | 3.9% | 96.1% | 98.24 |
| 24 | Acalabrutinib | 3.6% | 96.4% | 99.50 |
| 25 | Entrectinib | 3.6% | 96.4% | 93.69 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Darovasertib | 84.0% | 94.5% | -10.6% |
| Repotrectinib | 82.5% | 98.9% | -16.4% |
| Ponatinib | 79.5% | 96.7% | -17.2% |
| Cabozantinib | 42.6% | — | — |
| Pacritinib | 40.3% | 96.7% | -56.3% |
| Tivozanib | 31.7% | 96.1% | -64.4% |
| Ripretinib | 22.0% | — | — |
| Brigatinib | 15.4% | — | — |
| Defactinib | 14.7% | 91.7% | -77.0% |
| Quizartinib | 13.5% | — | — |
| Crizotinib | 12.2% | 97.3% | -85.1% |
| Pralsetinib | 11.6% | 99.4% | -87.8% |
| Abrocitinib | 11.2% | — | — |
| Sorafenib | 9.6% | — | — |
| Bosutinib | 8.0% | 95.6% | -87.6% |
| Idelalisib | 6.1% | — | — |
| Asciminib | 5.7% | — | — |
| Regorafenib | 5.1% | — | — |
| Avapritinib | 4.9% | — | — |
| Selumetinib | 4.9% | — | — |
| Rabusertib | 4.8% | — | — |
| Futibatinib | 4.4% | — | — |
| Zanubrutinib | 3.9% | — | — |
| Acalabrutinib | 3.6% | — | — |
| Entrectinib | 3.6% | 98.8% | -95.3% |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 13.8ms